Second Clinical Batch Released for Immediate Patient Use

• Second clinical batch of ALA-101 manufactured and released
• Sufficient supply to complete dose escalation and expansion
• Third batch expected before year-end to complete phase 1 trial
• Off-the-shelf manufacturing enhances patient access and speed
• Additional clinical sites activated for patient recruitment

Arovella Therapeutics Ltd has announced the release of a second clinical batch of its innovative CAR-iNKT therapy, ALA-101, demonstrating the scalability and reproducibility of its manufacturing process. This release provides sufficient material to complete dose escalation and initiate dose expansion in blood cancers. A third batch is expected by the end of the year, which is anticipated to complete the phase 1 trial. The off-the-shelf manufacturing approach addresses a significant bottleneck in conventional CAR-T therapies, potentially reducing costs and improving patient access. Additionally, new clinical trial sites in Melbourne, Sydney, and Brisbane have been activated to support patient screening and recruitment.